مقاله انگلیسی  CD38 در سرطان های پیشرفته پروستات
ترجمه نشده

مقاله انگلیسی CD38 در سرطان های پیشرفته پروستات

عنوان فارسی مقاله: CD38 در سرطان های پیشرفته پروستات
عنوان انگلیسی مقاله: CD38 in Advanced Prostate Cancers
مجله/کنفرانس: European Urology - ارولوژی اروپایی
رشته های تحصیلی مرتبط: پزشکی
گرایش های تحصیلی مرتبط: ارولوژی یا ادرار شناسی - خون و آنکولوژی
کلمات کلیدی فارسی: راه عبور اندونزین، لمفوسیت B، سزطان پروستات مقاوم به اخته کردن، CD38، التهاب، سلول میلوئیدی، پلاسماسیت، محیط ریز تومور، از کار افتادگی سلول T، سرطان پروستات
کلمات کلیدی انگلیسی: Adenosine pathway, B lymphocyte, Castration-resistant prostate cancer, CD38, Inflammation, Myeloid cell, Plasmacyte, Tumour microenvironment, T cell exhaustion, Prostate cancer
نوع نگارش مقاله: مقاله پژوهشی (Research Article)
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.eururo.2021.01.017
دانشگاه: Università della Svizzera Italiana, Switzerland
صفحات مقاله انگلیسی: 11
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2021
ایمپکت فاکتور: 6.362 در سال 2020
شاخص H_index: 216 در سال 2021
شاخص SJR: 9.799 در سال 2020
شناسه ISSN: 0302-2838
شاخص Quartile (چارک): Q1 در سال 2020
فرمت مقاله انگلیسی: PDF
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: خیر
آیا این مقاله مدل مفهومی دارد: ندارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: ندارد
آیا این مقاله فرضیه دارد: ندارد
کد محصول: E15538
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
نوع رفرنس دهی: vancouver
فهرست مطالب (انگلیسی)

 Abstract

Keywords

1. Introduction

2. Patients and methods

3. Results

4. Discussion

5. Conclusions

Appendix A. Supplementary data

References

بخشی از مقاله (انگلیسی)

Abstract

Background
CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have not been elucidated.

Objective
To characterise CD38 expression on prostate cancer (PC) epithelial cells and TIICs, and to associate this expression with clinical outcomes.

Design, setting, and participants
RNAseq from 159 patients with metastatic castration-resistant prostate cancer (mCRPC) in the International Stand Up To Cancer/Prostate Cancer Foundation (SU2C/PCF) cohort and 171 mCRPC samples taken from 63 patients in the Fred Hutchinson Cancer Research Centre cohort were analysed. CD38 expression was immunohistochemically scored by a validated assay on 51 castration-resistant PC (CRPC) and matching, same-patient castration-sensitive PC (CSPC) biopsies obtained between 2016 and 2018, and was associated with retrospectively collected clinical data.

Outcome measurements and statistical analysis
mCRPC transcriptomes were analysed for associations between CD38 expression and gene expression signatures. Multiplex immunofluorescence determined CD38 expression in PC biopsies. Differences in CD38+ TIIC densities between CSPC and CRPC biopsies were analysed using a negative binomial mixed model. Differences in the proportions of CD38+ epithelial cells between non-matched benign prostatic epithelium and PC were compared using Fisher’s exact test. Differences in the proportions of biopsies containing CD38+ tumour epithelial cells between matched CSPC and CRPC biopsies were compared by McNemar’s test. Univariable and multivariable survival analyses were performed using Cox regression models.

Results and limitations
CD38 mRNA expression in mCRPC was most significantly associated with upregulated immune signalling pathways. CD38 mRNA expression was associated with interleukin (IL)-12, IL-23, and IL-27 signalling signatures as well as immunosuppressive adenosine signalling and T cell exhaustion signatures. CD38 protein was frequently expressed on phenotypically diverse TIICs including B cells and myeloid cells, but largely absent from tumour epithelial cells. CD38+ TIIC density increased with progression to CRPC and was independently associated with worse overall survival. Future studies are required to dissect TIIC CD38 function.